Form 4: Contineum Therapeutics CSO Executes Stock Sale

Chief Scientific Officer Daniel S. Lorrain sold 4,170 shares of Contineum Therapeutics common stock via a 10b5-1 trading plan.

Summary

• Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics, Inc. (CTNM), sold a total of 4,170 shares of Class A Common Stock on May 1, 2026.
• The sales were executed in two tranches: 3,870 shares at a weighted average price of $13.06 and 300 shares at a weighted average price of $13.84.
• Following these transactions, the reporting person retains direct ownership of 143,542 shares, with an additional 6,842 shares held indirectly by a spouse.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-established 10b5-1 plan, which is a standard and transparent practice for executive liquidity.

Positives

• The sale was pre-planned under a Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering concerns regarding insider information.

Negatives

• The transaction represents a reduction in the direct equity stake held by a key member of the executive leadership team.

Risks

• Continued selling by insiders may be perceived negatively by the market, potentially impacting short-term share price sentiment.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider sales executed via 10b5-1 plans are common in the biotechnology sector, allowing executives to diversify holdings while maintaining compliance with SEC regulations.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate officers to manage equity compensation and avoid potential conflicts of interest.
• The volume of shares sold is relatively small compared to the total holdings of the reporting person, which is consistent with typical executive diversification strategies.

Stakeholder Impact

• Shareholders should note the reduction in insider ownership, though the pre-planned nature of the sale mitigates concerns regarding potential negative sentiment.

Key Dates

Keywords

Contineum Therapeutics, CTNM, Insider Trading, Form 4, Chief Scientific Officer, 10b5-1 Plan